Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving blood clotting factor
Reexamination Certificate
2006-03-14
2006-03-14
Saucier, Sandra E. (Department: 1651)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving blood clotting factor
C436S069000, C436S071000
Reexamination Certificate
active
07011956
ABSTRACT:
An assay to assess thrombotic risk in which oxidized lipids comprising phospholipids are utilized as a membrane source in a clotting assay and the results compared to an assay in which unoxidized phospholipid is used as a membrane source in the presence and absence of activated protein C (“APC”). The assay can monitor for the presence of antibodies in the patient which interfere specifically with the anticoagulant function of APC in an oxidation dependent or independent manner. This can indicate the propensity of the patient to experience episodes of vein thrombosis or arterial thrombosis.
REFERENCES:
Aviram, et al., 1991. “Oxidized low-density lipoprotein reduces plama coagulation in-vitro,”Scand J Lab Invest51:17-21.
Barrowcliffe, et al. 1981. “Studies of phospholipid reagents used in coagulation I: general properties and their sensitivity to Factor VIII,”Thromb Haemostas46:629-633.
Barrowcliffe, et al. 1981. “Phospholipid reagents used in coagulation II: factors influencing their sensitivity to heparin,”Thromb Haemostas46:634-637.
Billy, et al. 1995. “Prothrombin contributes to the assembly of the factor Va-factor Xa complex at phosphatidylserine-containing phospholipid membranes,”J Biol Chem270:26883-26889.
Esmon, C.T. and Schwarz, H.P. 1995. “An update on clinical and basic aspects of the protein C anticoagulant pathway,”Trends Cardiovasc Med5:141-148.
Esmon, et al. 2000. “Antiphospholipid antibodies and the protein C pathway,”J Autoimmunity15:221-225.
Furie, B. and Furie, B.C. 1988. “The molecular basis of blood coagulation,”Cell53:505-518.
Gilbert, G.E. and Arena, A.A. 1995. “Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-serine,”J Biol Chem270:18500-18505.
Horkko, et al. 1996. “Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids,”J Clin Invest98:815-825.
Jain, S.K. 1985. “In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats,”J Clin Invest76:281-286.
Lesnik, et al. 1995. “Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation,”Arteriosclerosis, Thrombosis and Vascular Biology15:1121-1130.
Malech, H.L. and Gallin, J.I. 1987. “Neutrophils in human diseases,”N Engl J Med317:687-694.
Mann, et al. 1988. “Cofactor proteins in the assembly and expression of blood clotting enzyme complexes,”Ann Rev Biochem57:915-956.
McCord, J.M. 1985. “Oxygen-derived free radicals in postischemic tissue injury,”N Engl J Med312:159-163.
Neuenschwander, et al. 1995. “Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhanceme of sensitivity to phosphatidylserine,”Biochemistry34:13988-13993.
Pei, et al. 1993. “Specific contribution of different phospholipid surfaces to the activation of prothrombin by the fully assembled prothrombinase,”J Biol Chem268:3226-3233.
Rauch, et al. 1986. “Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems,”J Biol Chem261:9672-9677.
Smeets, et al. 1996. “Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles,”Thromb Res81:419-426.
Smirnov, M.D. and Esmon, C.T. 1994. “Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein,”J Biol Chem269:816-819.
Smirnov, et al. 1995. “On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies,”J Clin Invest94:309-316.
Smirnov, et al. 1999. “The effect of membrane composition on the hemostatic balance,”Biochem38:3591-3598.
Esmon Naomi L.
Jamilabadi Omid Safa
Conley & Rose, P.C.
Hansen Eugenia S.
Oklahoma Medical Research Foundation
Saucier Sandra E.
LandOfFree
Thrombotic episode risk assays using oxidized phospholipids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thrombotic episode risk assays using oxidized phospholipids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thrombotic episode risk assays using oxidized phospholipids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3588737